Health
Hopeful Vigilance: What Parents Should Know About GLP-1s
Gen-GLP-1 has arrived. Parents need to be ready.
Posted September 25, 2026 Reviewed by Tyler Woods
Key points
- GLP-1 medicine use isn't limited to adults. Usage is also soaring among adolescents.
- Although clinical benefits of GLP-1 use are established among youth, there are unique concerns to consider.
- It is important for parents to understand the benefits and risks of GLP-1 use for their children
- Although parents can't replace a physician, there are many ways for them to monitor and intervene
Marcus, age 14, plays offensive line on his high school football team. His dream is to earn a football scholarship at his state university. And this season, he isn't gasping for air by the second quarter. Four months into a weekly GLP-1 injection prescribed for obesity and type 2 diabetes, his blood sugar is falling toward normal and his knees have stopped aching. But the nausea hits hardest on game days, his coach says he's lost some push off the line, and Marcus has a question he's too embarrassed to ask his doctor: Will this shot stop me from growing and performing my best?
Across town, Maya, age 15, is a competitive gymnast. No one prescribed her anything. A teammate's older sister sold her a vial of compounded semaglutide, and within weeks, her coach was praising how "light" she looked on the beam. Her parents noticed she was skipping dinner. They didn't notice anything else, however, until she misread the dosing units and spent a weekend unable to keep water down.
Between Hope and Fear
Marcus's mother is thrilled by his lab results and unsettled by every headline she reads. Maya's parents don't yet know there is anything to worry about. Between them sits a reality facing a growing number of families: GLP-1 medications are reaching young people faster than research can track what they do beyond the scale and the blood test. Among U.S. adolescents with obesity, the share with an active prescription rose roughly tenfold in the two and a half years after semaglutide was approved for teens,1 and prescribing is climbing among children as young as 8.2 For parents, the right stance is neither panic nor blind enthusiasm. It's hopeful vigilance.
GLP-1s for Youth: What We Know
In the largest teen trial, adolescents taking semaglutide reduced their BMI by about 16 percent over 68 weeks, while those on placebo gained slightly, results comparable to adults.3 A smaller trial in children ages 6 to 11 also showed meaningful benefit.4 Nausea, vomiting, and other stomach complaints are common, especially as doses increase, and gallstones occurred more often than with placebo.³
Large reviews haven't found that these drugs cause depression or suicidal thinking, and some teen studies even suggest lower risk.5 Still, some adults describe feeling flatter, more anxious, or less interested in things they used to enjoy, and teens with obesity already face higher rates of low mood. That's reason enough to keep watching.
Finally, the weight and other metabolic benefits fade when the medicine stops (just like in adults). Teens in trials began regaining weight within weeks of their last dose,3 so "How does this end?" belongs in the very first conversation.
GLP-1s in a Growing Body
Marcus's fear is understandable, but so far it isn't borne out: teen trials haven't shown short-term effects on growth or puberty.6 What they haven't measured is bone. Adolescence is when most of our lifetime skeleton is built, and in adults, semaglutide has been linked to modest losses in bone density.7 No published study has yet tracked bone density in teens on these drugs, and the first dedicated trial is scheduled to finish until 2030. That's why strength training and enough protein matter even more for Marcus than for his father.
Growth also changes what success looks like. For a growing child (unlike adults), doctors look at where BMI falls on the growth chart for age and sex, not simply the number on the scale. Holding weight steady while getting taller can be real progress.
A Developing Mind
Arguably the biggest risky unknown for adolescent GLP-1 use is eating disorders. On one hand, clinicians report that GLP-1s may quiet binge eating for some teens.8 But for a girl like Maya, already restricting and already praised for thinness, an appetite suppressant can deepen a dangerous pattern. A published case report describes exactly that in an adolescent girl,9 and pediatric experts urge prescribers to screen for restrictive and avoidant eating before treatment begins. Yet research on how these drugs change teens' eating remains scarce.
A Social Life Built Around Food
Teens eat together: team dinners, sleepovers, pizza, and restaurants after the game. A medicine that erases appetite can subtly pull a teen out of those bonding moments. For Marcus, whose size is part of his identity on the line, shrinking can feel like psychological loss as much as gain. These drugs also create a new parenting question: Who holds the injection pen, a teen building independence or a parent keeping watch?
Maya's story isn't hypothetical, either. U.S. poison-center reports involving GLP-1s among 6- to 17-year-olds rose nearly fiftyfold between 2017 and 2024, and compared with adults, these young people were about eight times more likely to have misused the drug intentionally.10 Sports that prize thinness or require making weight, such as gymnastics, dance, and wrestling, deserve extra attention.
What Parents Can Do
No parent can monitor what science hasn't yet measured. But you can watch what matters most. The checklist below gathers the essentials. Bring it to your child's appointments.
Epilogue
Marcus stayed on his medication. His doctor and coach worked with him to add a strength program and moved the conversation from pounds to the growth chart, where he's still climbing. Maya's parents found the vial, and a pediatrician and an eating disorder specialist are now guiding her recovery. Two teens, one class of medicine, very different stories. Hopeful vigilance requires making room for both.
References
1. Kim C, Sharifi M, Ross JS, et al. GLP-1 receptor agonist prescriptions for adolescents with obesity and associated disparities. JAMA Pediatr. Published online January 20, 2026. doi:10.1001/jamapediatrics.2025.5708
2. Babak J. Orandi, Suhani S. Patel, Mary Jo Messito, Michal A. Mankowski, Dorry L. Segev, Allan B. Massie; Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019–2026. Pediatrics 2026; e2026077048. 10.1542/peds.2026-077048
3. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601.
4. Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S; SCALE Kids Trial Group. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. N Engl J Med. 2025 Feb 6;392(6):555-565. doi: 10.1056/NEJMoa2407379.
5. Silva CFXCA, de Souza BL, Thomazini G, Júnior J, de Mendonça Bisneto OI, de Abreu I, Konstantyner T, Abreu M. GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026 Aug;28(8):6735-6743. doi: 10.1111/dom.70864.
6. Haider MA, Javed H. GLP-1 receptor agonists in adolescents: emerging endocrine, reproductive, and psychosocial concerns. J Pediatr Adolesc Gynecol. Published online June 28, 2026. doi:10.1016/j.jpag.2026.06.017
7. Hansen MS, Wölfel EM, Jeromdesella S, Møller JK, Ejersted C, Jørgensen NR, Eastell R, Hansen SG, Frost M. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine. 2024 May 3;72:102624. doi: 10.1016/j.eclinm.2024.102624.
8. Jebeile H, Danielsen YS, Sumithran P, Lorien S, Jardine IR, Baur LA, Lister NB. GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. Obes Rev. 2026 Apr;27(4):e70049. doi: 10.1111/obr.70049.
9. Liekens L, Kaïret K, Elst EF. Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report. BJPsych Open. 2025 Dec 1;12(1):e2. doi: 10.1192/bjo.2025.10909.
10. Senthilkumar, A., Hays, H.L., Kistamgari, S. et al. Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017–2024. J. Med. Toxicol. 22, 263–274 (2026). https://doi.org/10.1007/s13181-026-01128-6
